{"id":"m-vtd-pace","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"M-VTD-PACE combines bortezomib (proteasome inhibitor), thalidomide (immunomodulator), dexamethasone (corticosteroid), cisplatin, doxorubicin, cyclophosphamide, and etoposide. The regimen works by inhibiting proteasome function, modulating immune response, and providing direct cytotoxic chemotherapy. This multi-agent approach is designed to overcome drug resistance and improve outcomes in multiple myeloma patients, particularly those with high-risk disease.","oneSentence":"M-VTD-PACE is a combination chemotherapy and immunotherapy regimen that uses multiple agents to target and kill multiple myeloma cells through different mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:58.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (high-risk disease)"},{"name":"Relapsed/refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT00081939","phase":"PHASE2","title":"UARK 2003-33, Total Therapy III","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-01","conditions":"Multiple Myeloma","enrollment":303}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Melphalan","Velcade","Thalidomide","Dexamethasone","Cisplatin"],"phase":"phase_3","status":"active","brandName":"M-VTD-PACE","genericName":"M-VTD-PACE","companyName":"University of Arkansas","companyId":"university-of-arkansas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"M-VTD-PACE is a combination chemotherapy and immunotherapy regimen that uses multiple agents to target and kill multiple myeloma cells through different mechanisms. Used for Multiple myeloma (high-risk disease), Relapsed/refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}